Holen Sie sich die Stockscreener-App
0.368
6.36%
-0.025
Schlusskurs vom Vortag:
$0.393
Offen:
$0.4
24-Stunden-Volumen:
211.89K
Relative Volume:
0.27
Marktkapitalisierung:
$7.93M
Einnahmen:
$275.60K
Nettoeinkommen (Verlust:
$-8.33M
KGV:
-0.7967
EPS:
-0.4619
Netto-Cashflow:
$-5.40M
1W Leistung:
-22.12%
1M Leistung:
+13.41%
6M Leistung:
-54.30%
1J Leistung:
-67.14%
1-Tages-Spanne:
$0.368
$0.40
1-Wochen-Bereich:
$0.368
$0.4671
52-Wochen-Spanne:
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
Firmenname
Nexalin Technology Inc
Sektor
Branche
Telefon
(832) 260-0222
Adresse
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.368 | 7.93M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc Aktie (NXL) Neueste Nachrichten
Nexalin Technology Inc (NXLIW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nexalin Technology Inc (NXL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Inc (NXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc (NXLIW) Institutional Confidence - TradingKey
Nexalin Technology Inc (NXLIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nexalin Technology Adopts Second Amended and Restated Bylaws Effective June 16, 2026 - Minichart
Nexalin Technology Inc (NXLIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework - TipRanks
Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rules - Stock Titan
Nexalin abstracts accepted at NYC neuromodulation conference By Investing.com - Investing.com South Africa
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXLIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nexalin Technology Inc (NXLIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXLIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference - marketscreener.com
Nexalin abstracts accepted at NYC neuromodulation conference - Investing.com
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - GlobeNewswire
Exclusive: Nexalin Brazil trial shows benefits across anxiety, sleep and quality of life - MSN
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Amid Continued Development PhaseEarnings Outlook Update - newsline.com
Nexalin reports positive results from anxiety disorder trial By Investing.com - Investing.com Nigeria
NXL Should I Buy - Intellectia AI
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life - Sahm
Nexalin Technology, Inc. (NXL) stock price, news, quote and history - Yahoo Finance Australia
Nexalin Technology Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains 2%ROA Comparison - newsline.com
NXL Q1 2026 Earnings: EPS Misses Estimates, Stock Gains Despite Wider LossEarnings Surprise Score - newsline.com
Nexalin reports positive clinical trial results for anxiety and insomnia - grafa.com
Nexalin reports positive results from anxiety disorder trial - Investing.com UK
Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial - Moomoo
Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression - Quiver Quantitative
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sale - 富途牛牛
Nexalin receives U.S. patent for neurostimulation method - Investing.com UK
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - markets.businessinsider.com
Nexalin receives U.S. patent for neurostimulation method By Investing.com - Investing.com South Africa
Nexalin Technology Announces Issuance of U.S. Patent - GlobeNewswire
New brain stimulation patent targets anxiety, depression, insomnia - Stock Titan
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment - Sleep Review
Nexalin Technology (NXL) Surges 16%: Breakout Potential Above ResistanceValue ETF - The Legal Advocate
Nexalin Technology earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Nexalin Technology earnings beat, revenue fell short of estimates - Investing.com
Nexalin Technology Q1 2026 Earnings: EPS Misses Estimates Amidst Narrowing LossesProfit Margin Analysis - The Legal Advocate
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Stock Surges on No Revenue - newsline.com
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Company Intensifies R&D SpendSegment Revenue Breakdown - newsline.com
Nexalin Technology, Inc.Common Stock (NQ: NXL - The Chronicle-Journal
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - Sahm
Finanzdaten der Nexalin Technology Inc-Aktie (NXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):